Astellas and taysha gene therapies announce strategic investment to support development of taysha's aav-based gene therapy programs

- taysha gene therapies is an emerging leader in the development of aav gene therapies; new collaboration aimed at enhancing development of two of taysha's novel product candidates for rare monogenic central nervous system diseases with serious unmet medical needs - - astellas to invest a total of $50 million to acquire 15% of the company and to receive an exclusive option to obtain an exclusive license for tsha-102 for rett syndrome  and tsha-120 for giant axonal neuropathy (gan) - - astellas to receive certain rights related to any potential change of control of taysha - - astellas to receive one board observer seat on the taysha board of directors - tokyo and dallas , oct. 24, 2022 /prnewswire/ -- astellas pharma inc. (tse: 4503, president and ceo: kenji yasukawa, ph.d., "astellas") and taysha gene therapies, inc. (nasdaq: tsha, ceo: ra session ii, "taysha") today announced a strategic investment to support the advancement of taysha's adeno-associated virus (aav) gene therapy development programs for the treatment of rett syndrome and gan.
TSHA Ratings Summary
TSHA Quant Ranking